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Viral Load and 
Crimean-Congo 
Hemorrhagic Fever 
To the Editor: Crimean-Congo 
hemorrhagic fever (CCHF) is a severe 
viral disease transmitted to humans 
by tick bite or contact with blood, ex-
creta, or tissues of infected patients or 
livestock. The disease is endemic in 
many African, Asian, and European 
countries. Sporadic cases or outbreaks 
have been observed in the Balkan 
Peninsula (1–5). Prompt diagnosis of 
the disease is essential for preventing 
human-to-human transmission. Re-
verse transcription–PCR (RT-PCR) 
is the detection method of choice in 
ﬁ  rst days of illness and in severe cases 
with no antibody production. In recent 
years, real-time RT-PCR approaches 
have been described for detection and 
quantiﬁ   cation of CCHF virus (6–8). 
However, no information is available 
on viral RNA concentration in patients. 
We describe a real-time RT-PCR for 
detection and quantiﬁ  cation of CCHF 
virus, present the results of its use with 
clinical samples, and report the rela-
tionship between viral load and sever-
ity and outcome of CCHF.
We tested 29 serum samples from 
Albanian patients with suspected 
CCHF or their contacts who were liv-
ing in a CCHF-endemic area of Al-
bania. Serum samples were collected 
during 2003–2006 and categorized 
into 3 groups. Group A contained 
samples from 11 patients with CCHF 
conﬁ  rmed by a conventional RT-nest-
ed PCR (9). Group B contained sam-
ples from 5 patients who had negative 
RT-nested PCR results and positive 
serologic results. Group C contained 
samples from 15 persons who were 
from the same region as the CCHF pa-
tients but who did not have any clini-
cal symptoms of CCHF and had nega-
tive PCR or serologic results.
One set of primers and 1 probe 
were designed to amplify an 84-bp 
genome region of the S RNA segment 
of CCHF virus on the basis of Euro-
pean sequences (Balkan and Russian 
strains available in GenBank): primers 
CCEuS 5′-TGACAGCATTTCTTTA-
ACAGACATCA-3′ and CCEuAs 5′-
AAACACGGCAGCCTTAAGCA-3′, 
and probe 5′-TCGCCAGGGACTT-
TATATTCTGCAAGG-3′. A 25-μL 
reaction was conducted in a LightCy-
cler (Roche, Indianapolis, IN, USA) 
with 10 mmol/L of each deoxynucleo-
tide triphosphate, 600 nmol/L of each 
primer, 200 nmol/L of probe, and 3 
μL of RNA. Cycling conditions were 
50°C for 30 min and 95°C for 15 min, 
followed by 45 cycles at 95°C for 15 
s and 58°C for 30 s. A quantiﬁ  cation 
curve was constructed with 10-fold 
serial dilutions of in vitro–transcribed 
CCHF virus RNA. Positive results 
were obtained up to a dilution of 10−12, 
which corresponds to ≈45 virus ge-
nome equivalents (geqs) per reaction.
Twelve samples had positive re-
sults: all 11 samples in group A and 
1 in group B (Table). Results for the 
remaining samples in groups B and 
C were negative. Levels of tumor ne-
crosis factor-α (TNF-α), interleukin-6 
(IL-6), IL-10, and a 60-kDa soluble 
receptor of TNF were previously mea-
sured in most of the samples in this 
study (10), and their values are shown 
in the Table.
Viral loads ranged from 14 × 
106 to 28.99 × 106 geqs/reaction. The 
highest level was observed in the pa-
tient who died (23/03). High loads 
were observed in all primary case-pa-
tients (23/03, 82/03, 178/04, 252/06) 
except for patient 154/04, from whom 
a sample was obtained 18 days after 
onset of disease. All primary case-
patients had severe disease with high 
fever and clinically apparent hemor-
rhage. All secondary case-patients, 
except patient 34/03, were contacts 
of the patient who died (24b/03, hus-
band; 25b/03, brother-in-law; 50/03 
and 52/03, cousins; 56/03, sister-
in-law; 40/03, son of sister) and had 
symptoms of disease ≈1 week after the 
death of patient 23/03. 
Viral load of secondary case-pa-
tients was <250 geqs/reaction, which 
was much lower than that of primary 
case-patients. This ﬁ  nding  suggests 
that the disease is more severe in 
primary case-patients and becomes 
a milder form in secondary case-pa-
tients. Samples of secondary case-
patients 24b/03 and 25b/03 were ob-
tained on day 9 of illness, and patient 
24b/03 had a 4× higher viral load than 
patient 25b/03. A possible explanation 
might be that because patient 24b/03 
had closer contact with the person 
who died, he received a higher dose 
of virus, which might affect severity 
of the disease. Other secondary case-
patients had milder symptoms with no 
clinically apparent hemorrhage and 
were not hospitalized. All hospitalized 
patients had leukopenia, except for 
the patient whose sample was taken 
18 days after the onset of disease. No 
correlation was observed between vi-
ral load and cytokine levels or platelet 
counts, which suggests that other fac-
tors are involved in pathogenicity and 
immune response.LETTERS
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The real-time RT-PCR was rapid 
and more sensitive than the RT-nested 
PCR because 1 additional positive 
sample was detected. Samples with 
positive results from the ﬁ  rst  round 
of the conventional RT-nested PCR 
(23/03, 178/04, 252/06) had the high-
est viral loads when tested by real-
time RT-PCR.
In conclusion, a 1-step real-time 
RT-PCR for detection and quantiﬁ  ca-
tion of CCHF virus was developed, 
used with clinical samples, and pro-
vided informative data on the severity, 
course, and outcome of CCHF. Further 
studies, preferably in serial samples of 
patients, should provide insights into 
the pathology of CCHF and the effec-
tiveness of antiviral drugs.
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Table. Epidemiologic, molecular, and clinical data for 12 Albanian patients with suspected Crimean-Congo hemorrhagic fever, 2003–
2006*
Patient
Day of 
illness 
In
hospital Outcome
Real-time
RT-PCR, 
geqs/reaction IFA
TNF-α,
pg/mL
sTNF-R, 
ng/mL
IL-6,
pg/mL
IL-10,
pg/mL
Leukocytes, 
× 10
9/L
Platelets,
× 10
9/L
Group A primary 
23/03 6 Yes D 28,990,000 + 68.5 14.0 109.7 388.3 1,700 36,200
82/03 5 Yes R 450 + N N 17.0 23.9 2,300 96,830
154/04 18 Yes R 33 + ND ND ND ND 15,000 71,400
178/04 4 Yes R 7,271,000 + ND ND ND 4,100 62,550
252/06 2 Yes R 4049 – ND ND ND ND 3,700 117,900
Group A secondary 
24b/03 9 Yes R 166 + 1,444.8 N 114.2 N 4,800 63,800
25b/03 9 Yes R 40 + N N 10.3 N 3,800 63,000
50/03 3 No R 240 – N N N 43.4 ND ND
52/03 3 No R 18 – N N N 9.9 ND ND
56/03 5 No R 62 + N N 26.1 N ND ND
34/03 5 Yes R 46 – N 8.9 N N 8,000 102,000
Group B secondary 
40/03 7 No R 14 + N N N 23.1 ND ND
*RT-PCR, reverse transcription–PCR; geqs, genome equivalents; IFA, immunofluorescent assay; TNF-α, tumor necrosis factor-α; sTNF-R, soluble 
TNF-α receptor; IL-6, interleukin-6; D, died; +, positive; R, recovered; N, normal value; ND, not done; –, negative.   